Behavior of a novel monoclonal antibody for investigation of ovarian cancer and with possible involvement in multiple drug resistance.
Monoclonal antibodies (MAbs) were raised to an ovarian cancer cell line, OAW42, derived from a patient with a histology of serous cystadenocarcinoma of the ovary, in an attempt to identify novel antigens with a possible role in cancer medicine. One antibody P1H10, subclass IgG1, with a high titer was isolated and shown to recognize an antigen of 48 kDa. Enzyme-linked immunosorbent assay and immunocytochemical studies showed the presence of the target antigen in a number of carcinoma cell lines, including lung and breast, and in two out of three frozen breast tissue specimens. The antigen was not detected in normal human lymphocytes and there was minimal binding of the antibody to normal buccal cells. The antigen was not secreted by the OAW42 or the HepG2 cell lines and was not detected in the sera of a number of ovarian cancer patients. Indirect immunofluorescence studies confirmed the localization of the antigen to be intracellular. The binding of the antibody P1H10 to a number of multidrug resistant variants of the OAW42 cell line showed that the presence and the localization of the antigen in the drug-sensitive parental line and resistant variant cell lines was distinctly different and varied with the degree of drug resistance. The relative specificity of the antibody suggests it may be a possible diagnostic agent in human cancer. A possible role of the antigen in multiple drug resistance (MDR) is also suggested.